Alloy Therapeutics Launches Proprietary AntiClastic™ Antisense Oligonucleotide Platform to Make Potent Genetic Medicine
AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) is a proprietary platform available exclusively through partnerships with Alloy. Sudhir Agrawal, D.Phil, inventor of the underlying IP for the AntiClastic ASO platform, to chair Alloy’s genetic medicines scientific advisory board (SAB). BOSTON, Mass. – June 28, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its […]
Alloy Therapeutics Raises $42 Million Series D Financing to Accelerate Discovery Technology Development Across Biologic Modalities
— Following a successful expansion from antibodies into T-cell receptors and genetic medicines, Alloy will broaden its pre-competitive discovery technology and discovery services to enable innovative new therapeutic formats — BOSTON, MA; October 03, 2022—Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing led by its existing investors 8VC and Mubadala […]
Alloy Therapeutics Ecosystem Offerings Go Intracellular Through Collaboration with Sudhir Agrawal in Genetic Medicines
–Through a partnership with antisense pioneer Agrawal’s Arnay Sciences, Alloy strengthens its mission to democratize enabling drug discovery technology for the global scientific community– BOSTON, MA; June 09, 2022–Alloy Therapeutics, a biotechnology ecosystem company, announced a collaboration and licensing agreement with Sudhir Agrawal’s Arnay Sciences to advance new RNA-based drug discovery platforms and novel chemistries spanning […]
How Alloy Will Help the Drug Discovery Community Unlock the Therapeutic Potential of ASOs
Our mission has always been to democratize biologics discovery technology and capabilities so that the widest possible audience of scientists can access them to develop promising therapeutics for patients. We both create platforms and build discovery services groups that are expert in using and improving these platforms for the benefit of all. We are excited […]
Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering
The Basel, Switzerland-based deepCDR team and technology will strengthen Alloy’s antibody discovery platform and services for its ecosystem of 100+ global partners Boston, MA, USA and Basel, Switzerland, December 9th, 2021 – Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and […]
